| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
|
Medicine details |
|
| Medicine name | golimumab (Simponi®) |
| Formulation | 50 mg solution for injection |
| Reference number | 44 |
| Indication | In combination with methotrexate (MTX) for the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drug therapy including MTX has been inadequate. Golimumab has also been shown to improve physical function in this patient population |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 29/04/2010 |
| NICE guidance | |